Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Xvivo Perfusion AB ( (SE:XVIVO) ) is now available.
XVIVO Perfusion AB reported preliminary one-year follow-up data from the U.S. PRESERVE trial evaluating its hypothermic oxygenated perfusion heart technology, Heart Assist Transport, in extended criteria donor and donation after circulatory death hearts. The study enrolled 141 transplant recipients across 14 U.S. centers and met its pre-specified primary endpoints, with a 92.1% overall success rate at 30 days, 91.4% patient survival at one year, and a 7.9% incidence of severe primary graft dysfunction at 24 hours.
The median out-of-body time for donor hearts was 291 minutes and nearly three-quarters of hearts were preserved for more than four hours, underscoring the system’s potential to mitigate ischemic time constraints compared with standard static cold storage. XVIVO’s management framed the results as an important step in advancing organ preservation and broadening the use of higher-risk donor hearts, and said the company plans to submit the PRESERVE data to the U.S. Food and Drug Administration for review later this year, a move that could be pivotal for its U.S. market ambitions if the investigational device ultimately gains approval.
The most recent analyst rating on (SE:XVIVO) stock is a Buy with a SEK225.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
XVIVO Perfusion AB is a Swedish medical technology company focused on organ preservation solutions that extend the life of all major organs for transplantation. Founded in 1998 and listed on Nasdaq Stockholm under the ticker XVIVO, the company supports transplant teams globally through specialized technologies and research aimed at expanding the pool of viable donor organs and improving transplant outcomes.
Average Trading Volume: 151,164
Technical Sentiment Signal: Buy
Current Market Cap: SEK9.37B
For detailed information about XVIVO stock, go to TipRanks’ Stock Analysis page.